Trethera is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, with its lead focus on advanced solid tumors supported by two featured combination programs and parallel advancement of autoimmune and neurodegeneration programs on the same mechanism.
TRE-515 is a first-in-class oral therapy targeting the Salvage Pathway across cancer, autoimmune disease, and ALS, and Trethera evaluates it as a monotherapy in patients with advanced solid tumors.
541700 (legacy numeric)Scientific Research and Development ServicesEdition: UnknownReference ID: 963; Assignment ID: 2406859Primary: Yes; Current: Yes
541710 (legacy numeric)Research and Development in the Physical, Engineering, and Life SciencesEdition: UnknownReference ID: 961; Assignment ID: 2406836Primary: Yes; Current: Yes
541714 (legacy numeric)Research and Development in Biotechnology (except Nanobiotechnology)Edition: UnknownReference ID: 314651; Assignment ID: 2406814Primary: Yes; Current: Yes
SIC
8700 (legacy numeric)Engineering, Accounting, Research, Management, And Related ServicesEdition: UnknownReference ID: 208; Assignment ID: 2406649Primary: Yes; Current: Yes
8040 (legacy numeric)Offices And Clinics Of Other Health PractitionersEdition: UnknownReference ID: 566; Assignment ID: 2406765Primary: No; Current: Yes
8049 (legacy numeric)Offices And Clinics Of Health Practitioners, Not Elsewhere ClassifiedEdition: UnknownReference ID: 570; Assignment ID: 2406740Primary: No; Current: Yes